Wave Life Sciences offers an exciting new obesity treatment that can translate to big gains ahead, according to Wells Fargo. The bank reiterated the Singapore-based biotech name as overweight and hiked its price target to $29 per share from $16. This updated forecast implies an upside ahead of more than 57%. Wave Life Sciences has surged 50% this year, adding 147% alone on Monday after announcing positive interim data from a Phase 1 trial of an RNA obesity shot which helped cut fat without muscle loss. WVE YTD mountain WVE YTD chart In the note, Burnett called the stock's Monday surge "warranted as these data help de-risk a new [mechanism of action] in a potentially large market," he wrote. "Not only that, but we think there's a scenario where WVE-007 emerges with a competitive profile to

See Full Page